Written questions by Fortune.

Innovation and Technology, what steps she is taking to ensure that competition in fixed telecommunications infrastructure is sustained and protects consumers’ long-term interests.

Awaiting answer.

Innovation and Technology, what assessment she has made of the impact of increased competition in fixed telecommunications infrastructure on (a) household broadband bills, (b) service choice and (c) broadband speeds in the UK over the last five years.

Awaiting answer.

Innovation and Technology, what assessment she has made of the potential merits to consumers of competition in fixed telecommunications infrastructure.

Awaiting answer.

Innovation and Technology, with reference to the regulatory dashboard, published on 21 October 2025, if she will publish the letters sent to 19 regulators on enabling safe AI-powered innovation.

On 28th January 2026, DSIT SoS wrote to 19 regulators as part of the AI Action Plan anniversary. These letters asked regulators to work with DSIT and their sponsor department to publish a plan setting out how they will enable safe AI-powered innovation by May 2026, including clear, ambitious goals to enable safe AI adoption and responsible innovation; and to report annually on how their regulatory approach has enabled innovation and growth driven by AI in their sector. A copy of the letter sent to regulators has been published on gov.uk.

Innovation and Technology, how much funding the Government provided for research into psoriasis in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into atopic dermatitis in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into pemphigus in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into alopecia in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into acne in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into rosacea in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into vitiligo in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into epidermolysis bullosa in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into basal cell carcinoma in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into melanoma in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into hidradenitis suppurativa in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into actinic keratosis in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into squamous cell carcinoma in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into scleroderma in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, what the total amount of Government investment into otitis media with effusion research was in 2023-24; and which public bodies provided that investment.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.

Innovation and Technology, what the total amount of Government investment into neurofibromatosis research was in 2023-24; and which public bodies provided that investment.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.